A federal judge in Maine has put the brakes on a pilot program that would have enabled biopharma companies to offer rebates instead of discounts as part of the 340B program beginning Jan. 1, 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback